Recent studies have shown that decreased TFPI1 [11] levels or increased TFPI2 [15,16] levels are associated with an increased risk of thromboembolism in cancer patients, suggesting that TFPI1 and TFPI2 may exhibit different biological activities. This evidence concerns the gene TFPI and cancer.